DarioHealth (NASDAQ:DRIO) Stock Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Shares of DarioHealth Corp. (NASDAQ:DRIO) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $11.80 and traded as low as $10.10. DarioHealth shares last traded at $10.13, with a volume of 3,507 shares.

Analysts Set New Price Targets

DRIO has been the subject of a number of research reports. TD Cowen reiterated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Wall Street Zen cut shares of DarioHealth from a “hold” rating to a “sell” rating in a research note on Sunday, January 25th. Finally, Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DarioHealth currently has a consensus rating of “Hold” and an average target price of $38.00.

DarioHealth Stock Performance

The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41. The stock has a market cap of $68.46 million, a price-to-earnings ratio of -0.91 and a beta of 1.16. The stock’s fifty day moving average is $11.59 and its 200-day moving average is $11.80.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd grew its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the quarter. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.